The global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market is estimated to have reached $13.40bn in 2018 and is expected to grow at a CAGR of 4.43% in the first half of the forecast period. The stimulants submarket held 75% of the global Attention Deficit Hyperactivity Disorder (ADHD) Market in 2018.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 151-page report you will receive 124 charts– all unavailable elsewhere.
The 151-page report provides clear detailed insight into the ADHD market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029
• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by leading drugs:
• Amphetamine
• Methylphenidate
• Lisdexamfetamine
• Dexmethylphenidate
• Atomoxetine
• Guanfacine
• Clonidine
• Other Drugs
• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by drug type:
• Stimulants
• Non-stimulants
• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by patient type:
• Adult
• Children
• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 national market:
• The U.S.
• Germany
• France
• The U.K.
• Italy
• Spain
• China
• Japan
• India
• Brazil
• Russia
• This report discusses the selected leading companies:
• Eli Lilly
• Johnson and Johnson
• Lupin Limited
• Mallinckrodt & Co.
• Neos Therapeutics
• Pfizer Inc.
• Purdue Pharma L.P.
• Takeda Pharmaceuticals
• This report provides a SWOT Analysis and Porter’s Five Forces Analysis of the Attention Deficit Hyperactivity Disorder Drugs market.
• Key questions answered by this report:
• How is the ADHD market evolving?
• What is driving and restraining the ADHD market?
• What are the market shares of each segment of the overall ADHD market in 2018?
• How will each ADHD submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each ADHD’s submarket develop from 2018 to 2029?
• Which individual products will prevail and how will these shifts be responded to?
• What will be the main driver for the overall market from 2018 to 2029?
• How will political and regulatory factors influence the regional markets and submarkets?
• Will leading national vaccine markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2029 and which geographical region will lead the market in 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2018 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market. You find data, trends and predictions.
Buy our report today Attention Deficit Hyperactivity Disorder Drugs Market Forecast: Amphetamine, Methylphenidate Hydrochloride, Dexymethylphenidate, Lisdexamfetamine, Atomoxetine, Guanfacine, Clonidine, Stimulants, No-stimulants, Adults, Children, Retail Pharmacy, Hospital Pharmacy.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Overview
1.2 Global ADHD Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Attention Deficit Hyperactivity Disorder
2.1 History of ADHD
2.1.1 ADHD Medication Timeline
2.2 Signs and Symptoms
2.2.1 Inattention
2.2.2 Hyperactivity-Impulsivity
2.2.3 Impulsiveness
2.3 When can ADHD be diagnosed?
2.4 Side Effects & Risk Factors
2.5 Treatment and Therapies
2.5.1 Medication
2.5.2 Stimulants
2.5.3 Non-stimulants
2.5.4 Psychotherapy
2.5.5 Social Skills Training
2.6 Most Common Disorders That Can Accompany ADHD?
2.7 Blockbuster ADHD Drugs in 2018 - Leading Brands
3. ADHD: World Market Forecast 2019-2029
3.1 ADHD Market Overview, 2018
3.2 The World Attention Deficit Hyperactivity Disorder Market
3.3 World Attention Deficit Hyperactivity Disorder Market: Sales Forecast 2019-2029
3.4 Changing Market Shares by Region 2018-2029
3.5 ADHD Market: Drivers and Restraints 2019-2029
3.5.1 ADHD Market: Drivers 2019-2029
3.5.2 Increase in Prevalence of the ADHD
3.5.3 Rising Government Support
3.5.4 Growing Number of Regulatory Approvals for Drugs
3.5.5 Escalating of Mental Healthcare Awareness
3.5.6 ADHD Market Restraints: 2019-2029
3.5.7 Drug Abuse is a major factor that limits market growth
3.5.8 Stringent Government Regulations
3.5.9 Lack of ideal treatment for ADHD
3.5.10 The social stigma of ADHD and other mental illness
4. ADHD Market by Drugs, 2019-2029
4.1 Market Overview
4.2 Market Forecast 2019-2029
4.3 Market Share of ADHD by Drugs
4.3.1 Amphetamines: Market Forecast, 2018-2029
4.3.2 Methylphenidate: Market Forecast, 2018-2029
4.3.3 Dexmethylphenidate: Market Forecast, 2018-2029
4.3.4 Lisdexamfetamine: Market Forecast, 2018-2029
4.3.5 Atomoxetine: Market Forecast, 2018-2029
4.3.6 Guanfacine: Market Forecast, 2018-2029
4.3.7 Clonidine: Market Forecast, 2018-2029
4.3.8 Other Drugs: Market Forecast, 2018-2029
5. ADHD Market by Drug Type, 2019-2029
5.1 Market Overview
5.2 Market Forecast 2019-2029
5.3 Market Share of ADHD by Drug Type
5.4 Stimulants Market
5.5 Non-stimulants Market
6. ADHD Market by Patient Type 2019-2029
6.1 Market Overview
6.2 Market Forecast 2018-2029
6.3 Market Share of ADHD by Patient Type
6.4 Children ADHD Market
6.5 Adult (Aged 18 and above) ADHD Market
7. ADHD Market by Distribution Channel 2019-2029
7.1 Market Overview
7.2 Market Forecast 2018-2029
7.3 Market Share of ADHD by Patient Type
7.4 Retail Pharmacy Market
7.5 Hospital Pharmacy Market
8. Leading National Markets 2019-2029
8.1 Geographical Breakdown of the World ADHD Market
8.2 Global ADHD Market: Regional Forecast 2019-2029
8.3 How Will Regional Market Shares Change to 2029?
8.4 The US Attention Deficit Hyperactivity Disorder Market, 2019-2029
8.4.1 The US ADHD Market Forecast 2019-2029
8.5 The EU5 ADHD Market, 2019-2029
8.5.1 The EU5 ADHD Market Forecast 2019-2029
8.5.2 Germany ADHD Market Forecast 2019-2029
8.5.3 UK ADHD Market Forecast 2019-2029
8.5.4 French ADHD Market Forecast 2019-2029
8.5.5 Italian ADHD Market Forecast 2019-2029
8.5.6 Spanish ADHD Market Forecast 2019-2029
8.6 The Japanese ADHD Market 2019-2029
8.6.1 The Japanese ADHD Market Forecast 2019-2029
8.7 The Chinese ADHD Market 2019-2029
8.7.1 The Chinese ADHD Market Forecast 2019-2029
8.8 The Indian ADHD Market 2019-2029
8.8.1 The Indian ADHD Market Forecast 2019-2029
8.9 The Brazilian ADHD Market 2019-2029
8.9.1 The Brazilian ADHD Market Forecast 2019-2029
8.10 Russia ADHD Market 2019-2029
8.10.1 Russia ADHD Market Forecast 2019-2029
9. Leading Companies in the ADHD Market
9.1 Eli Lilly
9.1.1 Product Portfolio
9.1.2 Financial Overview
9.2 Johnson and Johnson
9.2.1 Product Portfolio
9.2.2 Financial Overview
9.3 Pfizer Inc.
9.3.1 Products Portfolio
9.3.2 Financial Overview
9.3.3 Recent Developments
9.4 G. Mallinckrodt & Co.
9.4.1 Product Portfolio
9.4.2 Financial Overview
9.5 Takeda Pharmaceuticals
9.5.1 Product Portfolio
9.5.2 Financial Overview
9.5.3 Recent Developments
9.6 Lupin Limited
9.6.1 Product Portfolio
9.6.2 Financial Overview
9.6.3 Recent developments
9.7 Purdue Pharma L.P.
9.7.1 Products Portfolio
9.7.2 Recent Developments
9.8 Neos Therapeutics
9.8.1 Product Portfolio
9.8.2 Financial Overview
9.8.3 Recent Developments
10. ADHD Market Qualitative Analysis
10.1 ADHD Market: SWOT Analysis
10.1.1 Strengths
10.1.2 Demand from Emerging Market Continues
10.1.3 Promising R&D Pipeline
10.1.4 Increasing Awareness
10.1.5 Government support
10.1.6 Weaknesses
10.1.7 High Manufacturing Costs
10.1.8 Opportunities
10.1.9 Technological Advancements
10.1.10 Alternative Treatment
10.1.11 Threats
10.1.12 Oligarchic Presence of Pharmaceutical Giants
10.1.13 Barriers to Market Entry
10.2 ADHD Market: Porters Five Forces Analysis
10.2.1 Bargaining Power of Supplier: Moderate
10.2.2 Bargaining Power of Buyer: Moderate
10.2.3 Competitive Rivalry: High
10.2.4 The Threat of New Entrants: Moderate
10.2.5 Threat of Substitutes: Moderate
11. Conclusion
11.1 The World ADHD Market in 2018 and 2019
11.2 World ADHD Market Forecast 2019-2029
11.3 Current Leading ADHD Segments
11.4 Leading ADHD Companies
11.5 Leading Regional Markets
11.6 The Future of the ADHD Market
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 2.1 ADHD Medication Timeline
Table 2.2 Blockbuster ADHD Drugs in 2018 - Leading Brands
Table 3.1 Global ADHD Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 3.2 Recent ADHD Drug Approvals
Table 4.1 Global ADHD Market Forecast by Drugs: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.2 Global Amphetamines Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 4.3 Global Methylphenidate Hydrochloride Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 4.4 Global Dexmethylphenidate Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 4.5 Global Lisdexamfetamine Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 4.6 Global Atomoxetine Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 4.7 Global Guanfacine Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 4.8 Global Clonidine Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 4.9 Global Other Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 5.1 Global ADHD Market Forecast by Drug Type: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 5.2 Global Stimulants Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 5.3 Global Non-stimulants Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 6.1 Global ADHD Market Forecast by Patient Type: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 6.2 Global Children ADHD Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 6.3 Global Adult ADHD Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 7.1 Global ADHD Market Forecast by Distribution Channel: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 7.2 Global Retail Pharmacy Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 7.3 Global Hospital Pharmacy Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2018-2029
Table 8.1 World ADHD Market by Region: Revenue ($Bn) and Market Share (%) 2018 and 2029
Table 8.2 Global ADHD Market Forecast by Region: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.3 US ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.4 EU5 ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.5 EU5 ADHD Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.6 Germany ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.7 UK ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.8 French ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.9 Italian ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.10 Spanish ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.11 Japanese ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.12 Chinese ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.13 Indian ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.14 Brazilian ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.15 Russia ADHD Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 9.1 Overview: Eli Lilly
Table 9.2 Product Portfolio: Eli Lilly
Table 9.3 Overview: Johnson & Johnson
Table 9.4 Product Portfolio: Johnson & Johnson
Table 9.5 Overview: Pfizer, Inc.
Table 9.6 Product Portfolio: Pfizer, Inc.
Table 9.7 Generic Drugs: Pfizer, Inc.
Table 9.8 Recent Developments: Pfizer, Inc.
Table 9.9 Overview: Mallinckrodt
Table 9.10 Product Portfolio: Mallinckrodt
Table 9.11 Overview: Takeda
Table 9.12 Product Portfolio: Takeda
Table 9.13 Recent Developments: Takeda
Table 9.14 Overview: Lupin, Ltd.
Table 9.15 Product Portfolio: Lupin, Ltd.
Table 9.16 Recent Developments: Lupin, Ltd.
Table 9.17 Overview: Purdue Pharmaceuticals L.P.
Table 9.18 Product Portfolio: Purdue Pharmaceuticals L.P.
Table 9.19 Recent Developments: Purdue Pharmaceuticals L.P.
Table 9.20 Overview: Neos Therapeutics
Table 9.21 Product Portfolio: Neos Therapeutics
Table 9.22 Overview: Neos Therapeutics
Table 10.1 ADHD Market: SWOT Analysis
List of Figures
Figure 3.1 Global ADHD Market Forecast Revenue ($bn), AGR (%) 2018-2029
Figure 3.2 Global ADHD Market Forecast Share (%) by Region 2018-2029
Figure 3.3 ADHD Market: Drivers and Restraints 2019-2029
Figure 4.1 Global ADHD Market Forecast by Drugs Market Revenue ($bn) 2018-2029
Figure 4.2 Global ADHD Market Forecast by Drugs: Market Share (%) 2018-2029
Figure 4.3 Global ADHD Market Forecast by Drugs: Market Shares (%), 2018
Figure 4.4 Global ADHD Market Forecast by Drugs: Market Shares (%), 2024
Figure 4.5 Global ADHD Market Forecast by Drugs: Market Shares (%), 2029
Figure 4.6 Global Amphetamines Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 4.7 Global Methylphenidate Hydrochloride Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 4.8 Global Dexmethylphenidate Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 4.9 Global Lisdexamfetamine Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 4.10 Global Atomoxetine Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 4.11 Global Guanfacine Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 4.12 Global Clonidine Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 4.13 Global Other Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 5.1 Global ADHD Market Forecast by Drug Type Market Revenue ($bn) 2018-2029
Figure 5.2 Global ADHD Market Forecast by Drug Type Market Share (%) 2018-2029
Figure 5.3 Global ADHD Market Forecast by Drug Type: Market Shares (%), 2018
Figure 5.4 Global ADHD Market Forecast by Drug Type: Market Shares (%), 2024
Figure 5.5 Global ADHD Market Forecast by Drug Type: Market Shares (%), 2029
Figure 5.6 Global Stimulants Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 5.7 Global Non-stimulants Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.1 Global ADHD Market Forecast by Patient Type Market Revenue ($bn) 2018-2029
Figure 6.2 Global ADHD Market Forecast by Patient Type Market Share (%) 2018-2029
Figure 6.3 Global ADHD Market Forecast by Patient Type: Market Shares (%), 2018
Figure 6.4 Global ADHD Market Forecast by Patient Type: Market Shares (%), 2024
Figure 6.5 Global ADHD Market Forecast by Patient Type: Market Shares (%), 2029
Figure 6.6 Global Children ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.7 Global Adult ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.1 Global ADHD Market Forecast, By Distribution Channel Market Revenue ($bn) 2018-2029
Figure 7.2 Global ADHD Market Forecast by Distribution Channel Market Share (%) 2018-2029
Figure 7.3 Global ADHD Market Forecast by Distribution Channel: Market Shares (%), 2018
Figure 7.4 Global ADHD Market Forecast by Distribution Channel: Market Shares (%), 2024
Figure 7.5 Global ADHD Market Forecast by Distribution Channel: Market Shares (%), 2029
Figure 7.6 Global Retail Pharmacy Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.7 Global Hospital Pharmacy Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.1 Global ADHD Market by Region: Revenues (%), 2018
Figure 8.2 Global ADHD Market by Region: Revenues (%), 2024
Figure 8.3 Global ADHD Market by Region: Revenues (%), 2029
Figure 8.4 US ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.5 EU5 ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.6 EU5 ADHD Market by Country: Revenue ($bn), 2018-2029
Figure 8.7 EU5 ADHD Market by Country: Revenue Share (%), 2018-2029
Figure 8.8 Germany ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.9 UK ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.10 French ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.11 Italian ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.12 Spanish ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.13 Japanese ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.14 Chinese ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.15 Indian ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.16 Brazilian ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.17 Russia ADHD Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 9.1 Eli Lilly: Financial Overview, 2015-2017
Figure 9.2 Johnson and Johnson: Financial Overview, 2015-2017
Figure 9.3 Pfizer, Inc.: Financial Overview: 2016-2018
Figure 9.4 Mallinckrodt Financial Overview: 2018
Figure 9.5 Takeda Pharmaceuticals: Financial Overview 2016- 2018
Figure 9.6 Lupin Limited: Financial Overview 2016-2018
Figure 9.7 Neos Therapeutics: Financial Overview 2016-2018
Figure 11.1 Worldwide ADHD Market Revenue, ($bn) 2018-2029
Figure 11.2 Global ADHD Market Forecasts: Regional Market Sizes ($bn), 2018, 2024, & 2029
Figure 11.3 ADHD Market Forecasts: Regional Market Share (%), 2018-2029
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
